Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins

  title={Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins},
  author={G{\'e}rard Bastian and Sa{\"i}k Urien and Françoise Br{\'e}e and Pascale Jolliet and Isabelle Rocher and Olivier Crambes and Jean Paul Tillement},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
SummaryThe binding of racemic tertatolol and 4-hydroxytertatolol and of their enantiomers was compared in α1-acid glycoprotein and albumin solutions. The binding rate of S(-)tertatolol to α1-acid glycoprotein was much greater than that of R(+)tertatolol, the binding of the racemate being intermediate. It was the reverse for the binding to albumin, although the differences were slight. The binding of 4-hydroxytertatolol racemate and enantiomers was very low as compared to the binding of… 



Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma.

In solutions containing ALB at a constant concentration and alpha 1-AGP at increasing concentrations, the binding of both isomers increases but the stereo selectivity is evident throughout the alpha 1,AGP concentration range examined.

Stereoselective binding of propranolol to human plasma, α1‐acid glycoprotein, and albumin

The stereoselective plasma binding of the (−)‐enantiomer of propranolol could limit the access of this more active enantiomer to β‐receptors or other active sites.

The stereoselectivity of the 'single drug binding site' of human alpha 1-acid glycoprotein (orosomucoid).

It is concluded that the single drug binding site of alpha 1-AGP is only slightly stereoselective and that the stereOSElective binding of the drugs investigated is probably of no clinical consequence.

Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration

The data show that the free fraction of the basic drug tertatolol in serum is affected by pathological conditions that cause changes in AAG concentration, which could account for 57% of intersubject variability in the bound/free ratio.

Biodisposition of tertatolol in man: a review.

The kinetics are linear over a 10-fold dosage range and, after repeated dosing, there is no accumulation, which justifies halving the dose in patients with cirrhosis and prothrombin time less than 70%.

Stereospecificity of beta-adrenoceptor blockade and renal vasodilatation by tertatolol.

It is concluded that both beta-adrenoceptor blockade and renal vasodilatation are stereospecific for the l-isomer of tertatolol.

Tertatolol preserves renal perfusion in patients with arterial hypertension after head injury.

Tertatolol is a potent beta-blocking agent comparable to propranolol apart from the fact that it preserves renal perfusion; this peculiar effect is related to a redistribution of the reduced cardiac output to the benefit of the kidney.